MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Adaptive Biotechnologies Corporation Accounts Receivables 2011-2026 | ADPT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Adaptive Biotechnologies Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.4 M | 41.7 M | 38 M | 40.1 M | 17.4 M | 10 M | 12.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.4 M | 10 M | 30 M |
Quarterly Accounts Receivables Adaptive Biotechnologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.8 M | 44.3 M | 43.6 M | 41.7 M | 40.8 M | 35.6 M | 42 M | 38 M | 31.2 M | 31.5 M | 31 M | 40.1 M | 26.5 M | - | 22.5 M | 17.4 M | 17.1 M | 14.2 M | 19.8 M | 10 M | 10 M | 10 M | 10 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 4.81 M | 4.81 M | 4.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.8 M | 4.81 M | 23.7 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 20.22 | -2.32 % | $ 2.55 B |  USA |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.82 | -3.48 % | $ 4.47 M | China |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.73 | -2.49 % | $ 1.11 B |  Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
126 M | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
26 K | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Certara
CERT
|
104 M | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
3.41 M | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
287 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Genmab A/S
GMAB
|
34 M | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
25 M | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
426 M | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
96.8 M | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
3.77 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Immunovant
IMVT
|
2.08 M | $ 26.99 | -2.74 % | $ 4.09 B | USA |
 |
Inhibrx
INBX
|
373 K | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
66.8 K | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
Insmed Incorporated
INSM
|
141 M | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
800 K | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
3.43 M | $ 29.11 | -0.31 % | $ 1.69 B | USA |